- Home
- CANF vs PEV Comparison
CANF vs PEV Comparison
Compare CANF & PEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PEV
- Stock Information
- Founded
- CANF 1994
- PEV 2002
- Country
- CANF Israel
- PEV United States
- Employees
- CANF N/A
- PEV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PEV Auto Manufacturing
- Sector
- CANF Health Care
- PEV Consumer Discretionary
- Exchange
- CANF Nasdaq
- PEV Nasdaq
- Market Cap
- CANF 14.4M
- PEV 15.4M
- IPO Year
- CANF N/A
- PEV 2022
- Fundamental
- Price
- CANF $1.52
- PEV $0.30
- Analyst Decision
- CANF Strong Buy
- PEV
- Analyst Count
- CANF 2
- PEV 0
- Target Price
- CANF $14.00
- PEV N/A
- AVG Volume (30 Days)
- CANF 1.2M
- PEV 974.9K
- Earning Date
- CANF 02-03-2025
- PEV 01-07-2025
- Dividend Yield
- CANF N/A
- PEV N/A
- EPS Growth
- CANF N/A
- PEV N/A
- EPS
- CANF N/A
- PEV N/A
- Revenue
- CANF $667,000.00
- PEV $21,635,000.00
- Revenue This Year
- CANF $409.56
- PEV N/A
- Revenue Next Year
- CANF N/A
- PEV N/A
- P/E Ratio
- CANF N/A
- PEV N/A
- Revenue Growth
- CANF N/A
- PEV 324.30
- 52 Week Low
- CANF $1.29
- PEV $0.27
- 52 Week High
- CANF $4.69
- PEV $1.60
- Technical
- Relative Strength Index (RSI)
- CANF 41.02
- PEV 38.32
- Support Level
- CANF $1.41
- PEV $0.29
- Resistance Level
- CANF $1.54
- PEV $0.30
- Average True Range (ATR)
- CANF 0.10
- PEV 0.03
- MACD
- CANF 0.02
- PEV 0.00
- Stochastic Oscillator
- CANF 52.38
- PEV 5.56
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PEV Phoenix Motor Inc.
Phoenix Motor Inc is an electrification solutions provider for the commercial vehicle industry as well as other industries. It designs, develops, manufactures, assembles, and integrates electric drive systems and light and medium-duty electric vehicles (EVs) and markets and sells electric vehicle chargers for the commercial and residential markets. The company operates two primary brands, Phoenix Motorcars, which focuses on commercial products including medium-duty electric vehicles, chargers, and electric forklifts, and EdisonFuture which intends to offer light-duty electric vehicles.